The stock of KalVista Pharmaceuticals Inc (NASDAQ: KALV) has decreased by -2.76 when compared to last closing price of 9.80. Despite this, the company has experienced a -16.48% fall in its stock price over the last five trading sessions. businesswire.com reported 2024-11-12 that CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company’s website at www.kalvista.com. After the presentations,.
Is It Worth Investing in KalVista Pharmaceuticals Inc (NASDAQ: KALV) Right Now?
The 36-month beta value for KALV is at 0.85. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KALV is 32.32M, and currently, shorts hold a 21.26% of that float. The average trading volume for KALV on November 15, 2024 was 374.15K shares.
KALV’s Market Performance
KALV’s stock has seen a -16.48% decrease for the week, with a -21.17% drop in the past month and a -22.14% fall in the past quarter. The volatility ratio for the week is 5.96%, and the volatility levels for the past 30 days are at 6.09% for KalVista Pharmaceuticals Inc The simple moving average for the last 20 days is -15.22% for KALV stock, with a simple moving average of -22.34% for the last 200 days.
Analysts’ Opinion of KALV
Many brokerage firms have already submitted their reports for KALV stocks, with H.C. Wainwright repeating the rating for KALV by listing it as a “Buy.” The predicted price for KALV in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on June 15, 2020 of the previous year 2020.
SVB Leerink, on the other hand, stated in their research note that they expect to see KALV reach a price target of $31. The rating they have provided for KALV stocks is “Outperform” according to the report published on July 29th, 2019.
Needham gave a rating of “Buy” to KALV, setting the target price at $35 in the report published on March 20th of the previous year.
KALV Trading at -14.86% from the 50-Day Moving Average
After a stumble in the market that brought KALV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.54% of loss for the given period.
Volatility was left at 6.09%, however, over the last 30 days, the volatility rate increased by 5.96%, as shares sank -24.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.10% lower at present.
During the last 5 trading sessions, KALV fell by -16.83%, which changed the moving average for the period of 200-days by -39.71% in comparison to the 20-day moving average, which settled at $11.24. In addition, KalVista Pharmaceuticals Inc saw -22.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALV starting from Palleiko Benjamin L, who sale 7,352 shares at the price of $12.19 back on Sep 09 ’24. After this action, Palleiko Benjamin L now owns 250,800 shares of KalVista Pharmaceuticals Inc, valued at $89,622 using the latest closing price.
Audhya Paul K., the CHIEF MEDICAL OFFICER of KalVista Pharmaceuticals Inc, sale 2,135 shares at $12.40 during a trade that took place back on Aug 23 ’24, which means that Audhya Paul K. is holding 83,745 shares at $26,474 based on the most recent closing price.
Stock Fundamentals for KALV
Current profitability levels for the company are sitting at:
- -128.99 for the present operating margin
- 0.3 for the gross margin
The net margin for KalVista Pharmaceuticals Inc stands at -117.55. The total capital return value is set at -0.88. Equity return is now at value -90.84, with -78.65 for asset returns.
Based on KalVista Pharmaceuticals Inc (KALV), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -81.27.
Currently, EBITDA for the company is -134.28 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 363.73. The receivables turnover for the company is 0.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.55.
Conclusion
In conclusion, KalVista Pharmaceuticals Inc (KALV) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
